We found that 13 of the 23 tumours (57% of the total) harboured mutations in 19 genes belonging to pathways that control cell proliferation and survival, including the RB and PI3K/RAS signalling pathways, which are altered in 67% and 45% of ovarian cancers, respectively [62] (Figure 4D). The gene discussed is RB1; the disease is ovarian cancer.